HUP9901343A2 - P53 protein variánsok és gyógyászati felhasználásuk - Google Patents

P53 protein variánsok és gyógyászati felhasználásuk

Info

Publication number
HUP9901343A2
HUP9901343A2 HU9901343A HUP9901343A HUP9901343A2 HU P9901343 A2 HUP9901343 A2 HU P9901343A2 HU 9901343 A HU9901343 A HU 9901343A HU P9901343 A HUP9901343 A HU P9901343A HU P9901343 A2 HUP9901343 A2 HU P9901343A2
Authority
HU
Hungary
Prior art keywords
subject
pressor
needle
protein
protein variants
Prior art date
Application number
HU9901343A
Other languages
English (en)
Inventor
Laurent Bracco
Emmanuel Conseiller
Original Assignee
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S.A. filed Critical Rhone-Poulenc Rorer S.A.
Publication of HUP9901343A2 publication Critical patent/HUP9901343A2/hu
Publication of HUP9901343A3 publication Critical patent/HUP9901343A3/hu
Publication of HU225937B1 publication Critical patent/HU225937B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány tárgyát a p53 tűmőrszűpresszőr gén termékénekprőteinszármazékai képezik, melyek javítőtt fűnkciókkal rendelkeznek aterápiás használat szempőntjából. A találmány előnyösen őlyanfehérjékre vőnatkőzik, melyek javítőtt tűmőrszűpresszőr és aprőgramőzőtt sejthalált indűkáló tűlajdőnságőkkal rendelkeznek,különösen őlyan prőliferációs patőlógiás környezetben, ahől a vadtípűsú p53 prőtein inaktivált. A találmány tárgya az ezeket amőlekűlákat kódőló nűkleinsavak, az azőkat tartalmazó vektőrők, ésazők terápiás, pőntősabban génterápiás alkalmazása. ŕ
HU9901343A 1995-07-19 1996-07-17 Protein p53 variants and their therapeutical uses HU225937B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9508729A FR2736915B1 (fr) 1995-07-19 1995-07-19 Variants de la proteine p53 et utilisations therapeutiques

Publications (3)

Publication Number Publication Date
HUP9901343A2 true HUP9901343A2 (hu) 1999-08-30
HUP9901343A3 HUP9901343A3 (en) 2000-10-30
HU225937B1 HU225937B1 (en) 2008-01-28

Family

ID=9481133

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901343A HU225937B1 (en) 1995-07-19 1996-07-17 Protein p53 variants and their therapeutical uses

Country Status (22)

Country Link
US (2) US6326464B1 (hu)
EP (1) EP0839194B1 (hu)
JP (1) JPH11510378A (hu)
KR (1) KR100501881B1 (hu)
AT (1) ATE324442T1 (hu)
AU (1) AU725841B2 (hu)
BR (1) BR9611087A (hu)
CA (1) CA2224468C (hu)
CZ (1) CZ296185B6 (hu)
DE (1) DE69636072T2 (hu)
DK (1) DK0839194T3 (hu)
ES (1) ES2263161T3 (hu)
FR (1) FR2736915B1 (hu)
HU (1) HU225937B1 (hu)
IL (1) IL122991A (hu)
MX (1) MX9800555A (hu)
NO (1) NO322477B1 (hu)
PT (1) PT839194E (hu)
SK (1) SK286955B6 (hu)
TW (1) TW444022B (hu)
WO (1) WO1997004092A1 (hu)
ZA (1) ZA966127B (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1208438A (zh) 1995-07-28 1999-02-17 玛丽·柯里癌症治疗中心 转运蛋白及其应用
US6881571B1 (en) 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
FR2775984B1 (fr) * 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
FR2755144B1 (fr) * 1996-10-29 1998-11-27 Rhone Poulenc Rorer Sa Fragments d'anticorps a chaine unique anti-p53 et utilisation
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US5943914A (en) * 1997-03-27 1999-08-31 Sandia Corporation Master-slave micromanipulator apparatus
EP0979290A2 (en) 1997-04-28 2000-02-16 Aventis Pharma S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
IL121041A0 (en) 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
DE19751587A1 (de) 1997-11-21 1999-07-29 Hoechst Marion Roussel De Gmbh Onkogen- oder virusgesteuerte Expressionssysteme
EP1150688A4 (en) * 1998-10-19 2004-06-16 Yeda Res & Dev TREATING SYSTEMIC LUPUS ERYTHEMATODES BY REGULATING THE AUTOIMMUNE RESPONSE TO AUTOANTIGENS
US6831155B2 (en) * 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
US7196242B2 (en) * 2000-05-16 2007-03-27 The Regents Of The University Of California Methods for identifying novel therapeutics and diagnostics in the p53 pathway
US7534861B2 (en) * 2003-01-10 2009-05-19 Ambergen, Inc. Compositions and methods for immunoaffinity purification
US7772367B2 (en) * 2004-01-30 2010-08-10 The Trustees Of Columbia University In The City Of New York C-terminal p53 palindromic peptide that induces apoptosis of cells with aberrant p53 and uses thereof
US20060246143A1 (en) * 2005-04-28 2006-11-02 Hilmi Ege Targeted therapy via targeted delivery of energy susceptible nanoscale magnetic particles
KR100749858B1 (ko) * 2005-08-12 2007-08-16 연세대학교 산학협력단 ｐ53 변이체 및 그의 용도
US9186317B2 (en) * 2007-11-26 2015-11-17 Stc.Unm Active nanoparticles and method of using
EP2224961A1 (en) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
KR102092345B1 (ko) 2013-09-30 2020-03-24 삼성전자주식회사 류신 지퍼 변이체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559223A (en) * 1991-08-09 1996-09-24 E. I. Dupont De Nemours And Company Synthetic storage proteins with defined structure containing programmable levels of essential amino acids for improvement of the nutritional value of plants
GB9224784D0 (en) * 1992-11-26 1993-01-13 Univ Dundee Cellular protein
FR2710846B1 (fr) * 1993-10-04 1995-12-22 Rhone Poulenc Rorer Sa Compositions pharmaceutiques et leur utilisation, notamment dans le traitement des maladies neurogénératives.
US5700657A (en) * 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
AU1440695A (en) * 1993-12-21 1995-07-10 Sloan-Kettering Institute For Cancer Research P53-based polypeptide fragments, nucleic acid molecules encoding same, and uses thereof
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
WO1996016989A1 (en) 1994-11-28 1996-06-06 The Wistar Institute Of Anatomy And Biology p53 PROTEINS WITH ALTERED TETRAMERIZATION DOMAINS

Also Published As

Publication number Publication date
US6933373B2 (en) 2005-08-23
HU225937B1 (en) 2008-01-28
PT839194E (pt) 2006-08-31
ES2263161T3 (es) 2006-12-01
EP0839194B1 (fr) 2006-04-26
TW444022B (en) 2001-07-01
IL122991A (en) 2007-07-24
CZ296185B6 (cs) 2006-01-11
ATE324442T1 (de) 2006-05-15
NO980203L (no) 1998-03-10
SK6398A3 (en) 1998-09-09
NO322477B1 (no) 2006-10-09
SK286955B6 (sk) 2009-08-06
CA2224468C (fr) 2012-01-03
DE69636072T2 (de) 2006-11-30
WO1997004092A1 (fr) 1997-02-06
KR100501881B1 (ko) 2005-11-14
DK0839194T3 (da) 2006-08-28
FR2736915B1 (fr) 1997-08-22
HUP9901343A3 (en) 2000-10-30
FR2736915A1 (fr) 1997-01-24
US6326464B1 (en) 2001-12-04
MX9800555A (es) 1998-04-30
BR9611087A (pt) 1999-07-13
JPH11510378A (ja) 1999-09-14
AU725841B2 (en) 2000-10-19
CA2224468A1 (fr) 1997-02-06
IL122991A0 (en) 1998-08-16
US20020193561A1 (en) 2002-12-19
AU6618696A (en) 1997-02-18
KR19990029088A (ko) 1999-04-15
ZA966127B (en) 1997-02-10
CZ14498A3 (cs) 1998-04-15
EP0839194A1 (fr) 1998-05-06
DE69636072D1 (de) 2006-06-01
NO980203D0 (no) 1998-01-16

Similar Documents

Publication Publication Date Title
HUP9901343A2 (hu) P53 protein variánsok és gyógyászati felhasználásuk
EP0804609A4 (en) NEW GENES OF RESPONSE p53
HUP0202882A2 (en) Novel b7-4 molecules and uses therefor
HUP0003533A2 (hu) Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk
ATE273388T1 (de) Veränderte menschliche c3-proteine
HUP9802926A2 (hu) Apolipoprotein A-I új variánsai
EP1012603A4 (en) FUNCTIONAL FRAGMENTS OF THE HIV-1 VPR PROTEIN AND METHODS OF USE
FR2744455B1 (fr) Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications
HUP9904199A1 (hu) Egyláncú anti-p53 antitest fragmentumok és alkalmazásuk
ATE262034T1 (de) Xylanasen, für diese kodierende gene und anwendungen derselben
DE69936513D1 (de) Menschliche p51-gene und deren genprodukte
HUP9901346A2 (hu) Deltap62 polipeptid és variánsai, ezeket kódoló nukleinsav-szekvenciák és felhasználásuk
WO1996027015A3 (en) A novel gene for a protein kinase associated with drug resistance
SE9703287D0 (sv) Peptides
WO2002077190A8 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002018554A3 (en) Isolated human drug-metabolizing proteins, nucleic acid moleculesand uses thereof
WO2002072765A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
DE60120974D1 (de) Proteinkinase-molekül 14911 und dessen anwendungen
WO2002068648A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these humans ras-like proteins, and uses thereof
WO2002074976A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002079494A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002077193A8 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002068468A3 (en) Isolated human tumor supressor proteins, nucleic acid molecules encoding these human tumor supressor proteins, and uses thereof
WO2002074973A9 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002079407A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): DR. LANG TIVADARNE, S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

FH92 Termination of representative

Representative=s name: DR. LANG TIVADARNE, S.B.G. & K. SZABADALMI UEG, HU

MM4A Lapse of definitive patent protection due to non-payment of fees